Essentialis’ investigational compound DCCR has demonstrated a 30% to 40% reduction in triglyceride (TG) levels in a Phase 2b trial conducted with patients whose TG levels exceeded 500mg/dL.
DCCR is a crystalline salt of diazoxide, available in a controlled-release, once-a-day tablet formulation.
Go deeper with GlobalData
In the Phase 2b double-blind, placebo-controlled study, half of the subjects were included in the atorvastatin combination sub-group and the remaining were in the monotherapy / fenofibrate combination subgroup.
Patients in the atorvastatin combination sub-group received either DCCR 290mg or placebo in combination with atorvastatin 20mg for 18 weeks, while those in the monotherapy / fenofibrate subgroup were randomised to receive either DCCR 290mg or placebo for 12 weeks, followed by co-administration of fenofibrate (Trilipix) 135mg for another six weeks.
DCCR 290mg in combination with statin resulted in placebo-adjusted median reductions of 28% in TG, 51% in very low density lipoprotein-cholesterol (VLDL-C), and 16% in non-high density lipoprotein-cholesterol (non HDL-C) levels with an increase in HDL-C of 11%, the study reported.
See Also:
In combination with fenofibrate, DCCR showed median reductions in TG of 78%, in non-HDL-C of 34%, and an increase in HDL-C of 38%.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe study also showed that the increase in LDL-C was only 42% in the fenofibrate plus DCCR group when compared to 57% in the fenofibrate plus placebo group.
Following 18 weeks of treatment, DCCR demonstrated nearly a 40% improvement in HOMA-IR, a measure of insulin resistance, and a reduction in median weight of more than 3kg, compared to a worsening of HOMA-IR and no change in median weight in the placebo-treated subjects.
Essentialis president and chief executive officer Aaron D. Berg said: "Our plans to pursue next steps with DCCR are clear – we want to help patients reduce medical risks associated with very high triglyceride levels."
Essentialis board member and scientific advisory board head Richard Pasternak added: "These data clearly motivate us to advance DCCR into larger trials that may demonstrate benefit to patients with multiple disease risk factors."
Image: A crystalline salt of diazoxide has been found to show promise in a Phase 2b trial as monotherapy and in combination with existing lipid therapy. Photo: Benjah-bmm27
